{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:35:39Z","timestamp":1790400939819,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T00:00:00Z","timestamp":1500076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10875-017-0416-4","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T22:44:18Z","timestamp":1500072258000},"page":"539-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune\u00ae, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency"],"prefix":"10.1007","volume":"37","author":[{"given":"Gergely","family":"Krivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"Chernyshova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Kostyuchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Nyul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Derfalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Musial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kappler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Sadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Bernatowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,15]]},"reference":[{"key":"416_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2249.2009.03954.x","volume":"157","author":"B Gathmann","year":"2009","unstructured":"Gathmann B, Grimbacher B, Beaut\u00e9 J, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006\u20132008. Clin Exp Immunol. 2009;157:3\u201311.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"416_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1182\/asheducation-2003.1.314","volume":"2003","author":"M. D. Cooper","year":"2003","unstructured":"Cooper MD, Lanier LL, Conley ME, Puck JM. Immunodeficiency disorders. Hematology Am Soc Hematol Educ Program. 2003:314\u201330.","journal-title":"Hematology"},{"issue":"Pt 2","key":"416_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1258\/acb.2008.008175","volume":"46","author":"P Wood","year":"2009","unstructured":"Wood P. Primary antibody deficiency syndromes. Ann Clin Biochem. 2009;46(Pt 2):99\u2013108.","journal-title":"Ann Clin Biochem"},{"issue":"2 Suppl","key":"416_CR4","doi-asserted-by":"publisher","first-page":"S571","DOI":"10.1067\/mai.2003.86","volume":"111","author":"FA Bonilla","year":"2003","unstructured":"Bonilla FA, Geha RS. Primary immunodeficiency diseases. J Allergy Clin Immunol. 2003;111(2 Suppl):S571\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"416_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1006\/clim.2002.5241","volume":"104","author":"A Plebani","year":"2002","unstructured":"Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221\u201330.","journal-title":"Clin Immunol"},{"key":"416_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0091-6749(99)70085-0","volume":"104","author":"L Kainulainen","year":"1999","unstructured":"Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104:1031\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"416_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0022-3476(99)70246-5","volume":"134","author":"P Quartier","year":"1999","unstructured":"Quartier P, Debr\u00e9 M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589\u201396.","journal-title":"J Pediatr"},{"issue":"6","key":"416_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1067\/mai.2002.124999","volume":"109","author":"PJ Busse","year":"2002","unstructured":"Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001\u20134.","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 2","key":"416_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2249.2011.04390.x","volume":"164","author":"C Cunningham-Rundles","year":"2011","unstructured":"Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin Exp Immunol. 2011;164(Suppl 2):16\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"416_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2249.2012.04588.x","volume":"169","author":"HS Hernandez-Trujillo","year":"2012","unstructured":"Hernandez-Trujillo HS, Chapel H, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169(1):57\u201369.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"416_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","volume":"27","author":"ER Stiehm","year":"2013","unstructured":"Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171\u20138.","journal-title":"Transfus Med Rev"},{"key":"416_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000354893","volume":"38","author":"J Dantal","year":"2013","unstructured":"Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38:275\u201384.","journal-title":"Am J Nephrol"},{"issue":"5","key":"416_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/trf.12939","volume":"55","author":"I Quinti","year":"2015","unstructured":"Quinti I, Pulvirenti F, Milito C, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion. 2015;55(5):1067\u201374.","journal-title":"Transfusion"},{"issue":"1","key":"416_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/vox.12025","volume":"105","author":"MB Funk","year":"2013","unstructured":"Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang. 2013;105(1):54\u201364.","journal-title":"Vox Sang"},{"issue":"4","key":"416_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/vox.12192","volume":"107","author":"W Anani","year":"2014","unstructured":"Anani W, Triulzi D, Yazer MH, Qu L. Relative IgA-deficient recipients have an increased risk of severe allergic transfusion reactions. Vox Sang. 2014;107(4):389\u201392.","journal-title":"Vox Sang"},{"key":"416_CR16","unstructured":"Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). European Medicines Agency: EMA\/CHMP\/BPWP\/94033\/2007 rev.2."},{"key":"416_CR17","unstructured":"FDA Guidance for Industry on safety, efficacy and PK studies to support marketing of human IVGg as replacement therapy for primary humoral immunodeficiency 2008."},{"issue":"6","key":"416_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","volume":"40","author":"HW Schr\u00f6der","year":"2012","unstructured":"Schr\u00f6der HW, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012;40(6):601\u201311.","journal-title":"Infection"},{"issue":"3","key":"416_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2249.2010.04187.x","volume":"161","author":"W Kreuz","year":"2010","unstructured":"Kreuz W, Erd\u00f6s M, Rossi P, et al. A multi-centre study of efficacy and safety of Intratect\u00ae, a novel intravenous immunoglobulin preparation. Clin Exp Immunol. 2010;161(3):512\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"416_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1423-0410.2006.00764.x","volume":"90","author":"J Bj\u00f6rkander","year":"2006","unstructured":"Bj\u00f6rkander J, Nikoskelainen J, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90(4):286\u201393.","journal-title":"Vox Sang"},{"key":"416_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21\u201330.","journal-title":"Clin Immunol"},{"key":"416_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","volume":"135","author":"HW Eijkhout","year":"2001","unstructured":"Eijkhout HW, Van der Meer JWM, Kallenberg CGM, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann Intern Med. 2001;135:165\u201374.","journal-title":"Ann Intern Med"},{"issue":"6","key":"416_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1592\/phco.26.6.813","volume":"26","author":"T Koleba","year":"2006","unstructured":"Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26(6):813\u201327.","journal-title":"Pharmacotherapy"},{"issue":"3\u20134","key":"416_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejps.2009.02.014","volume":"37","author":"RL Wasserman","year":"2009","unstructured":"Wasserman RL, Church JA, Peter HH, et al. IgPro10 in PID study group pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci. 2009;37(3\u20134):272\u20138.","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl 1","key":"416_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-2249.2009.04023.x","volume":"158","author":"M Ballow","year":"2009","unstructured":"Ballow M, Notarangelo L, Grimbacher B, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158(Suppl 1):14\u201322.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"416_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1517\/14740338.2010.484419","volume":"9","author":"J Caress","year":"2010","unstructured":"Caress J, Kennedy B, Eickman K. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf. 2010;9(6):971\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"416_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaip.2013.09.012","volume":"1","author":"M Berger","year":"2013","unstructured":"Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract. 2013;1:558\u201366.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"416_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","volume":"136","author":"R Ameratunga","year":"2004","unstructured":"Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136(1):111\u20133.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"416_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1537-2995.1988.28188127947.x","volume":"28","author":"NM Heddle","year":"1988","unstructured":"Heddle NM, Kelton JG, Turchyn KL, Ali MA. Hypergammaglobulinemia can be associated with a positive direct antiglobulin test, a nonreactive eluate, and no evidence of hemolysis. Transfusion. 1988;28(1):29\u201333.","journal-title":"Transfusion"},{"issue":"2","key":"416_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/ajcp\/90.2.197","volume":"90","author":"YO Huh","year":"1988","unstructured":"Huh YO, Liu FJ, Rogge K, et al. Positive direct antiglobulin test and high serum immunoglobulin G values. Am J Clin Pathol. 1988;90(2):197\u2013200.","journal-title":"Am J Clin Pathol"},{"key":"416_CR31","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","volume":"20","author":"BM Koffman","year":"1997","unstructured":"Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102\u20137.","journal-title":"Muscle Nerve"},{"issue":"6","key":"416_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00002826-200311000-00009","volume":"26","author":"M Matsuda","year":"2003","unstructured":"Matsuda M, Hosoda W, Sekijima Y, et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol. 2003;26(6):306\u201311.","journal-title":"Clin Neuropharmacol"},{"key":"416_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1399-3038.2008.00741.x","volume":"20","author":"S Lemos","year":"2009","unstructured":"Lemos S, Jacob CMA, Pastorino AC, Castro APBM, Fomin ABF, Carneiro-Sampaio MMS, et al. Neutropenia in antibody-deficient patients under IVIG replacement therapy. Paed Allergy Immunol. 2009;20:97\u2013101.","journal-title":"Paed Allergy Immunol"},{"key":"416_CR34","first-page":"22","volume":"20","author":"MH Chae","year":"2013","unstructured":"Chae MH, Park SW, Jeon IS. An analysis of neutropenia after the administration of high-dose intravenous immunoglobulin or anti-D immunoglobulin on acute immune thrombocytopenic purpura children: age based analysis. Clin Pediatr Hematol Oncol. 2013;20:22\u20138.","journal-title":"Clin Pediatr Hematol Oncol"},{"key":"416_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.mph.0000155871.26380.84","volume":"27","author":"AE Niebanck","year":"2005","unstructured":"Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol. 2005;27:145\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"416_CR36","first-page":"177","volume":"320","author":"D Zeltser","year":"2000","unstructured":"Zeltser D, Fusman R, Chapman J, et al. Increased leukocyte aggregation induced by gamma-globulin: a clue to the presence of pseudoleukopenia. Am J Med Sci. 2000;320(3):177\u201382.","journal-title":"Am J Med Sci"},{"issue":"10","key":"416_CR37","doi-asserted-by":"publisher","first-page":"e26469","DOI":"10.1371\/journal.pone.0026469","volume":"6","author":"S Casulli","year":"2011","unstructured":"Casulli S, Top\u00e7u S, Fattoum L, et al. A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One. 2011;6(10):e26469.","journal-title":"PLoS One"},{"key":"416_CR38","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.intimp.2011.07.024","volume":"11","author":"A Baxley","year":"2011","unstructured":"Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2011;11:1663\u20137.","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-017-0416-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-017-0416-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-017-0416-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T15:13:30Z","timestamp":1566573210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-017-0416-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,15]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s10875-017-0416-4","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,15]]},"assertion":[{"value":"28 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"A. Bellon and A. Sadoun are LFB Biotechnologies employees. M. Kappler is the consultant for LFB Biotechnologies. All other co-authors were the study investigators and received investigator honoraria or funds for research from LFB Biotechnologies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}